EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

Tilki, D.; van den Bergh, RCN.; Briers, E.; Van den Broeck, T.; Brunckhorst, O.; Darraugh, J.; Eberli, D.; De Meerleer, G.; De Santis, M.; Farolfi, A.; Gandaglia, G.; Gillessen, S.; Grivas, N.; Henry, AM.; Lardas, M.; J L H van Leenders, G.; Liew, M.; Linares Espinos, E.; Oldenburg, J.; van Oort, IM.; Oprea-Lager, DE.; Ploussard, G.; Roberts, MJ.; Rouviere, O.; Schoots, IG.; Schouten, N.; Smith, EJ.; Stranne, J.; Wiegel, T.; Willemse, PM.; Cornford, P.

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

All Authors

Tilki, D.

van den Bergh, RCN.

Briers, E.

Van den Broeck, T.

Brunckhorst, O.

Darraugh, J.

Eberli, D.

De Meerleer, G.

De Santis, M.

Farolfi, A.

Show 10 more

LTHT Author

Henry, Ann

LTHT Department

Leeds Cancer Centre

Publication Date

2024

Item Type

Journal Article
Practice Guideline
Systematic Review

Abstract

BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines. METHODS: The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence. KEY FINDINGS AND LIMITATIONS: Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa. CONCLUSIONS AND CLINICAL IMPLICATIONS: Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/). PATIENT SUMMARY: This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.